The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice.
Troy L MerryAnna E S BrooksStewart W MassonShannon E AdamsJagdish K JaiswalStephen M F JamiesonPeter R ShepherdPublished in: International journal of obesity (2005) (2019)
Our results indicate that macrophage infiltration of adipose tissue induced by a high-fat diet may not be the trigger for impairments in whole body glucose homeostasis, and that anti-CSF1 therapies are not likely to be useful as treatments for insulin resistance.